
Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.
Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 1, 15 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Otitis Media (Ear Nose Throat Disorders) pipeline landscape.
Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache and loss of appetite. Risk factors include age, seasonal factors and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Otitis Media - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Otitis Media (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Otitis Media (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 1, 15 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Otitis Media (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Otitis Media (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Otitis Media (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Otitis Media (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Otitis Media (Ear Nose Throat Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Otitis Media (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Otitis Media (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Blue Water Vaccines Inc
Ceolia Pharma Co Ltd
Clarametyx Biosciences Inc
Earnano LLC
Furen Pharmaceutical Group Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Inventprise LLC
Laboratorios Salvat SA
Maxwell Biosciences Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MyX Therapeutics Inc
NTC srl
O-Ray Pharma Inc
Olymvax Biopharmaceuticals Inc
ProclaRx LLC
Vaxcyte Inc
Vyome Therapeutics Inc
Companies Mentioned
Blue Water Vaccines Inc
Ceolia Pharma Co Ltd
Clarametyx Biosciences Inc
Earnano LLC
Furen Pharmaceutical Group Co Ltd
Hunan Sanqing Pharmaceutical Co Ltd
Inventprise LLC
Laboratorios Salvat SA
Maxwell Biosciences Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
MyX Therapeutics Inc
NTC srl
O-Ray Pharma Inc
Olymvax Biopharmaceuticals Inc
ProclaRx LLC
Vaxcyte Inc
Vyome Therapeutics Inc
Table of Contents
63 Pages
- Introduction
- Global Markets Direct Report Coverage
- Otitis Media - Overview
- Otitis Media - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Otitis Media - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Otitis Media - Companies Involved in Therapeutics Development
- Blue Water Vaccines Inc
- Ceolia Pharma Co Ltd
- Clarametyx Biosciences Inc
- Earnano LLC
- Furen Pharmaceutical Group Co Ltd
- Hunan Sanqing Pharmaceutical Co Ltd
- Inventprise LLC
- Laboratorios Salvat SA
- Maxwell Biosciences Inc
- Merck & Co Inc
- MerLion Pharmaceuticals Pte Ltd
- MyX Therapeutics Inc
- NTC srl
- O-Ray Pharma Inc
- Olymvax Biopharmaceuticals Inc
- ProclaRx LLC
- Vaxcyte Inc
- Vyome Therapeutics Inc
- Otitis Media - Drug Profiles
- (ciprofloxacin hydrochloride + fluocinolone acetonide) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- aspoxicillin - Drug Profile
- Product Description
- Mechanism Of Action
- BWV-201 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CMTX-200 - Drug Profile
- Product Description
- Mechanism Of Action
- CMTX-301 - Drug Profile
- Product Description
- Mechanism Of Action
- Drug for Otitis Media - Drug Profile
- Product Description
- Mechanism Of Action
- Drugs for Otitis Media - Drug Profile
- Product Description
- Mechanism Of Action
- ENT-103 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- finafloxacin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IVT-25 - Drug Profile
- Product Description
- Mechanism Of Action
- NTC-011 - Drug Profile
- Product Description
- Mechanism Of Action
- OR-404IT - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- PCL-1440 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pneumococcal (13-valent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- pneumococcal (23-valent) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- pneumococcal polysaccharide [15-valent] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules for Chronic Suppurative Otitis Media (CSOM) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- solithromycin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tebipenem pivoxil - Drug Profile
- Product Description
- Mechanism Of Action
- Vaccine for Otitis Media - Drug Profile
- Product Description
- Mechanism Of Action
- VAX-24 - Drug Profile
- Product Description
- Mechanism Of Action
- VAX-XP - Drug Profile
- Product Description
- Mechanism Of Action
- VT-1917 - Drug Profile
- Product Description
- Mechanism Of Action
- Otitis Media - Dormant Projects
- Otitis Media - Discontinued Products
- Otitis Media - Product Development Milestones
- Featured News & Press Releases
- Dec 20, 2021: Clarametyx Biosciences awarded $3.15 million grant from NIH to advance a broad-spectrum vaccine technology for bacterial infections
- Oct 04, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement - Update on the commercialisation and research and development of Cetraxal Plus of the group
- Sep 01, 2021: NanoCarrier : Accomplishment of primary endpoint in phase III clinical study of ENT103
- May 31, 2021: NanoCarrier : Completion of patient enrollment for phase III trial with ENT103
- Jan 13, 2021: Lee’s Pharmaceutical Holdings: Voluntary announcement update on an investigational ear drug product
- Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
- May 18, 2017: Pediapharm Announces the Commercial Launch of Otixal in Canada
- Dec 27, 2016: OTOVEL's trials published in JAMA
- Dec 12, 2016: Pediapharm receives Health Canada approval for Otixal
- Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes
- May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes
- Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Otitis Media, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Otitis Media - Pipeline by Blue Water Vaccines Inc, 2022
- Otitis Media - Pipeline by Ceolia Pharma Co Ltd, 2022
- Otitis Media - Pipeline by Clarametyx Biosciences Inc, 2022
- Otitis Media - Pipeline by Earnano LLC, 2022
- Otitis Media - Pipeline by Furen Pharmaceutical Group Co Ltd, 2022
- Otitis Media - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2022
- Otitis Media - Pipeline by Inventprise LLC, 2022
- Otitis Media - Pipeline by Laboratorios Salvat SA, 2022
- Otitis Media - Pipeline by Maxwell Biosciences Inc, 2022
- Otitis Media - Pipeline by Merck & Co Inc, 2022
- Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, 2022
- Otitis Media - Pipeline by MyX Therapeutics Inc, 2022
- Otitis Media - Pipeline by NTC srl, 2022
- Otitis Media - Pipeline by O-Ray Pharma Inc, 2022
- Otitis Media - Pipeline by Olymvax Biopharmaceuticals Inc, 2022
- Otitis Media - Pipeline by ProclaRx LLC, 2022
- Otitis Media - Pipeline by Vaxcyte Inc, 2022
- Otitis Media - Pipeline by Vyome Therapeutics Inc, 2022
- Otitis Media - Dormant Projects, 2022
- Otitis Media - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Otitis Media, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.